2023
2022
2021
- 04/07/2021 - Time knowledge impairments in children with ADHD
- 02/17/2021 - The Course of ADHD during Pregnancy
2020
- 12/16/2020 - Remote Learning During COVID-19
- 10/13/2020 - Cannabis and ADHD – A CADDRA Policy Statement
- 08/19/2020 - ADHD as a Risk Factor for Infection with COVID-19
- 06/11/2020 - British Columbia Pharmacare Update
- 03/27/2020 - Vyvanse® Chewable Tablet added to Ontario Formulary
- 03/18/2020 - Attention Deficit Hyperactivity Disorder – ADHD
- 03/11/2020 - Impact of ADHD on Household Chores
- 01/28/2020 - Intuniv added to Ontario Formulary
2019
- 07/10/2019 - New indication and new reimbursement codes in Quebec
- 03/04/2019 - Disability Tax Credit Survey – An Update
- 02/27/2019 - Dimensions of Impulsivity
- 02/26/2019 - Cannabis use and driving-related performance
2018
- 02/28/2018 - BC Patients Urged to Support CADDAC Campaign
- 02/28/2018 - New Medication Option for adults with ADHD in Canada
2017
2016
2015
- 12/18/2015 - ODPRN Report Released in Ontario
- 11/10/2015 - New CADDRA ADHD Transition Form
- 10/27/2015 - Dispelling the Myths & Misinformation about ADHD
- 09/24/2015 - BC ADHD Advocacy Meeting: Friday, 16 October
- 04/02/2015 - CADDRA Response to Health Canada Alert
2013
- 11/01/2013 - CADDRA Rebuttal in National Post
- 11/01/2013 - New AAP Guidelines on ADHD
- 11/01/2013 - New Health Canada Information on Strattera
- 11/01/2013 - Vyvanse Approved on Ontario Formulary
- 11/01/2013 - Vyvanse now approved for all ages by Health Canada
2012
- 09/26/2012 - CADDRA Response to Toronto Star
2011
2010
2009
- 11/19/2009 - Revision of Biphentin starting doses